13F filer · CIK 1917529
Atlas Venture Life Science Advisors, LLC
CAMBRIDGE, MA · filing since Q4 2021 · last filing Aug 13, 2026
Reported value
$881.3M
+$91.3M vs prior
Positions
7
New / sold out
1 / 0
Added / reduced
1 / 3
Turnover
14.6%
buys $121.9M · sells $252.5M
Top-10 weight
100.0%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Kailera Therapeutics, Inc. | +5,171,282 | – | +$113.9M |
| Added | Q32 Bio, Inc. | +625,000 | +29.9% | +$8.0M |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | Kymera Therapeutics, Inc. | -1,730,467 | -37.8% | $-198.4M |
| Reduced | Dyne Therapeutics, Inc. | -2,330,366 | -25.5% | $-51.8M |
| Reduced | Korro Bio, Inc. | -174,265 | -15.3% | $-2.3M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Kymera Therapeutics, Inc.COMMON STOCK | 2,847,541 | $326.5M | 37.05% |
| 2 | Dyne Therapeutics, Inc.COMMON STOCK | 6,800,099 | $151.0M | 17.14% |
| 3 | Sionna Therapeutics, Inc.COMMON STOCK | 2,995,602 | $131.8M | 14.95% |
| 4 | Kailera Therapeutics, Inc.COMMON STOCK | 5,171,282 | $113.9M | 12.93% |
| 5 | Disc Medicine, Inc.COMMON STOCK | 1,513,875 | $110.7M | 12.56% |
| 6 | Q32 Bio, Inc.COMMON STOCK | 2,717,106 | $34.6M | 3.93% |
| 7 | Korro Bio, Inc.COMMON STOCK | 962,884 | $12.7M | 1.44% |